Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:37:45 EDT Tue 10 Sep 2024
Enter Symbol
or Name
USA
CA



Q:APTO - APTOSE BIOSCIENCES INC - http://aptose.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
APTO - Q0.80.349·0.39710.10.3599+0.01715.0158.7382780.352  0.3665  0.33163.71  0.3419:51:20Sep 0515 min RT 2¢

Recent Trades - Last 10 of 278
Time ETExPriceChangeVolume
19:51:20Q0.34940.00068
19:08:35Q0.36590.017131
18:20:13Q0.34910.000332
17:59:05Q0.35990.0111400
16:52:20Q0.34890.00015
16:32:20Q0.36590.017140
15:52:04Q0.36590.0171100
15:52:04Q0.36590.0171100
15:52:04Q0.36590.0171400
15:52:04Q0.36590.0171148

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-09-05 16:15U:APTONews ReleaseAptose Announces Results from Special Meeting of Shareholders
2024-08-30 16:30U:APTONews ReleaseAptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
2024-08-15 16:30U:APTONews ReleaseAptose Announces Adjournment of its Special Meeting of Shareholders
2024-08-08 17:07U:APTONews ReleaseAptose Reports Results for the Second Quarter 2024
2024-07-19 17:00U:APTONews ReleaseAptose Announces Receipt of Deficiency Notice from Nasdaq
2024-06-18 17:30U:APTONews ReleaseAptose Announces Results from Annual and Special Meeting of Shareholders
2024-06-14 07:30U:APTONews ReleaseAptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
2024-06-03 16:30U:APTONews ReleaseAptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-05-31 08:00U:APTONews ReleaseAptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-05-14 16:01U:APTONews ReleaseAptose Reports Results for the First Quarter 2024
2024-05-06 16:30U:APTONews ReleaseAptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
2024-03-26 16:01U:APTONews ReleaseAptose Reports Results for the Fourth Quarter and Full Year 2023
2024-03-18 16:30U:APTONews ReleaseAptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
2024-01-31 16:01U:APTONews ReleaseAptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
2024-01-26 08:00U:APTONews ReleaseAptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
2023-12-09 18:30U:APTONews ReleaseAptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
2023-11-30 17:00U:APTONews ReleaseAptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
2023-11-09 16:00U:APTONews ReleaseAptose Reports Results for the Third Quarter 2023
2023-11-02 09:00U:APTONews ReleaseAptose Tuspetinib Clinical Data Selected for Oral Presentation ‚  at the 2023 ASH Annual Meeting
2023-10-30 09:15U:APTONews ReleaseAptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib